ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. 

With more than 300 people employed by the Company, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe and a US head office. The Company's Development group is located in Galashiels, Scotland and Bedminster, New Jersey, US.

ProStrakan has been listed on the main London Stock Exchange since 2005.